AstraZeneca Pharma India Q1 FY27 Results: Revenue Jumps 30% to ₹682.8 Crore, Oncology and Biopharma Drive Growth
AstraZeneca Pharma India Limited (NSE: ASTRAZEN, BSE: 506820) reported a strong start to financial year 2026-27, with total revenue from operations rising 30% year-on-year to ₹682.8 crore in Q1 FY27.
The company’s June quarter performance was supported by continued growth across its key therapy areas, particularly Oncology, Biopharmaceuticals and Rare Disease. Alongside financial growth, AstraZeneca Pharma India achieved several regulatory milestones and launched strategic healthcare initiatives during the quarter.
AstraZeneca Pharma India Q1 FY27 Results: Key Highlights
| Financial Metric | Q1 FY27 |
|---|---|
| Total Revenue from Operations | ₹682.8 crore |
| Profit Before Exceptional Item & Tax | ₹51.0 crore |
| Profit After Exceptional Item & Tax* | ₹50.7 crore |
| Revenue Growth | 30% YoY |
*The company clarified that the phrase “Profit after exceptional item and tax” in the financial performance summary should be read as “Profit after exceptional item and before tax”, i.e. profit before tax.
The 30% revenue growth marks another strong quarter for AstraZeneca Pharma India and reflects sustained momentum in its portfolio of prescription medicines.
Oncology Leads AstraZeneca Pharma India’s Growth
Oncology remained the company’s largest therapy area during Q1 FY27.
The segment generated revenue of ₹464.9 crore, representing 26% growth compared with Q1 FY26.
The performance reflects continued demand for AstraZeneca’s oncology portfolio and the company’s focus on expanding access to innovative cancer treatments.
Biopharmaceuticals Revenue Rises 36%
The Biopharmaceuticals segment, covering CVRM, Respiratory & Immunology (R&I) and related therapies, recorded revenue of ₹161.9 crore.
The segment grew by an impressive 36% year-on-year.
This was one of the strongest contributors to AstraZeneca Pharma India’s overall growth during the quarter.
Rare Disease Business Shows Strong Momentum
The Rare Disease segment delivered revenue of approximately ₹14.4 crore, compared with the corresponding period last year, representing approximately 35-fold growth.
While the segment remains smaller in absolute revenue terms, the sharp increase highlights the company’s expanding presence in specialised and high-unmet-need therapies.
AstraZeneca Q1 FY27 Segment Performance
| Therapy Area | Q1 FY27 Revenue | YoY Growth |
|---|---|---|
| Oncology | ₹464.9 crore | 26% |
| Biopharmaceuticals | ₹161.9 crore | 36% |
| Rare Disease | ₹14.4 crore | ~35x |
The three therapy areas underline the breadth of AstraZeneca Pharma India’s portfolio and its focus on specialised healthcare segments.
Key Regulatory Approvals During Q1 FY27
AstraZeneca Pharma India secured multiple important regulatory approvals during the quarter.
Acalabrutinib for CLL and SLL
The company received regulatory approval for acalabrutinib in combination with venetoclax, with or without obinutuzumab, for the treatment of previously untreated patients with chronic lymphocytic leukaemia (CLL) and small lymphocytic lymphoma (SLL).
The approval expands treatment options in blood cancers and strengthens AstraZeneca’s oncology portfolio.
Acalabrutinib for Mantle Cell Lymphoma
Acalabrutinib also received approval in combination with bendamustine and rituximab for adult patients with previously untreated mantle cell lymphoma who are not eligible for autologous stem cell transplant.
This represents another regulatory milestone for AstraZeneca’s haematology-oncology franchise.
Trastuzumab Deruxtecan for HER2-Positive Breast Cancer
The company received regulatory approval for trastuzumab deruxtecan in combination with pertuzumab for the first-line treatment of adults with unresectable or metastatic HER2-positive breast cancer.
The approval further strengthens AstraZeneca’s position in advanced breast cancer treatment.
AI-Powered Lung Cancer Screening Initiative in Telangana
Beyond its product portfolio, AstraZeneca Pharma India also expanded its healthcare partnerships during the quarter.
The company signed a Memorandum of Understanding with the Government of Telangana to introduce AI-enabled lung cancer screening across public healthcare facilities.
Under the initiative, AstraZeneca will facilitate deployment of an AI-powered chest X-ray solution from Qure.ai.
The technology is designed to help clinicians identify high-risk pulmonary nodules and other lung conditions, supporting earlier triage and follow-up.
The programme is expected to cover 20 public healthcare facilities across urban and rural areas of Telangana.
The initiative will also include training and upskilling of healthcare professionals to support long-term adoption.
K+ Connect Initiative for Heart Failure and Kidney Disease
AstraZeneca launched K+ Connect, a pan-India multidisciplinary initiative focused on improving the management of hyperkalaemia among patients with heart failure and chronic kidney disease.
The initiative aims to bring clinicians from different specialties together to improve:
- Risk identification
- Patient monitoring
- Hyperkalaemia management
- Coordination across specialties
- Clinical awareness
The programme highlights AstraZeneca’s growing focus on integrated disease management rather than medicines alone.
India Coronary Conquest 2026
AstraZeneca also launched India Coronary Conquest (ICC) 2026 in collaboration with STEMI India.
The programme is designed as a national complex PCI challenge for interventional cardiologists.
It aims to strengthen evidence-based learning and peer-to-peer exchange through case-based learning and scientific collaboration.
The initiative is focused on capability building in advanced cardiovascular care across India.
AstraZeneca Pharma India Receives Industry Recognition
The company also received several awards during the quarter.
At the OPPI India Awards 2026, AstraZeneca Pharma India received the Medical Excellence Award for its contributions to Rare Disease.
The company was also named runner-up in the Marketing Excellence category for its Hyperkalaemia & Kidney Care initiative in Biopharmaceuticals.
AstraZeneca Pharma India also received a Gold Award at the ETHRWorld Employee Experience Awards 2026 in the Exceptional Employee Experience in Driving Business Impact category.
Management Commentary
Bhavana Agrawal, Chief Financial Officer & Director of AstraZeneca Pharma India, said the company delivered 30% growth in the first quarter, taking revenue to ₹682.8 crore.
She highlighted the company’s consistent double-digit growth track record over the past five years and said the company remains focused on investing strategically in opportunities that support sustainable long-term value creation.
Praveen Rao Akkinepally, Country President & Managing Director, said the first-quarter performance reflected the strength of AstraZeneca’s portfolio and its focus on expanding access to innovative medicines for patients in India.
What AstraZeneca Pharma India’s Q1 Results Mean for Investors
AstraZeneca Pharma India’s Q1 FY27 numbers point to strong momentum across its core businesses.
The most important positives include:
Strong overall growth: Revenue increased 30% year-on-year to ₹682.8 crore.
Oncology remains the core growth engine: The segment generated ₹464.9 crore, accounting for the majority of reported revenue.
Biopharmaceuticals accelerating: The 36% growth in the segment was ahead of overall company growth.
Rare Disease expanding rapidly: The segment delivered approximately 35-fold growth, albeit from a smaller base.
Strong product pipeline: Multiple regulatory approvals during the quarter could support future portfolio expansion.
Healthcare partnerships: The Telangana AI-enabled lung cancer screening programme demonstrates the company’s focus on technology-led healthcare access.